Roger Jeffs

“Today's call comes at an important moment for Liquidia, and I want to be direct about what connects our extraordinary performance since launch to what lies ahead.”

“As we look back on 2025 and forward into 2026, what stands out is the rapid establishment of our preferred product profile paired with precise execution. Last year demonstrated that Liquidity could launch, scale, and reach profitability quickly within only 120 days of launch, in fact.”

“This morning, I want to begin by expressing just how proud we are of what Liquidia has accomplished in a remarkably short period of time.”

“We are very pleased and excited to share our first commercial data for YUTREPIA with everyone this morning. It's been a spectacular beginning.”

“In a little more than 2 weeks, May 24 to be precise, we will have reached the PDUFA goal date for Liquidia’s first internally developed commercial product, YUTREPIA, an investigational inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension, or PAH, and pulmonary…”